Quince Therapeutics (NASDAQ:IRLA) Issues Earnings Results, Misses Expectations By $0.28 EPS

Quince Therapeutics (NASDAQ:IRLA) announced its quarterly earnings data on Friday. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.28), Zacks reports.

Quince Therapeutics Price Performance

Quince Therapeutics stock traded up $0.11 during midday trading on Friday, hitting $39.89. 46,391 shares of the company’s stock were exchanged, compared to its average volume of 183,072. Quince Therapeutics has a 12 month low of $15.10 and a 12 month high of $909.98. The stock has a market cap of $40.69 million, a price-to-earnings ratio of -0.25 and a beta of 1.78.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Weiss Ratings assumed coverage on shares of Quince Therapeutics in a research report on Tuesday, October 13th. They set a “sell (d-)” rating on the stock. Raymond James Financial raised shares of Quince Therapeutics to a “moderate buy” rating in a research note on Friday, October 9th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold”.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc. is a clinical-stage biotechnology company developing therapies for rare diseases and other conditions with significant unmet medical needs. The company’s technology platform is designed to use patients’ own red blood cells to deliver therapeutic compounds, with the goal of providing sustained treatment while limiting systemic exposure. Quince’s lead program is the EryDex System, an investigational treatment that loads dexamethasone sodium phosphate into a patient’s red blood cells for controlled release.